4//SEC Filing
EYEGATE PHARMACEUTICALS INC 4
Accession 0001144204-16-107341
$KPRXCIK 0001372514operating
Filed
Jun 6, 8:00 PM ET
Accepted
Jun 7, 5:42 PM ET
Size
23.9 KB
Accession
0001144204-16-107341
Insider Transaction Report
Form 4
GOLDBERG MORTON
Director
Transactions
- Sale
Common Stock
2016-06-03$3.37/sh−4,650$15,690→ 38,566 total - Sale
Common Stock
2016-06-07$3.31/sh−746$2,473→ 32,277 total - Exercise/Conversion
Common Stock
2016-06-03$0.65/sh+33,775$21,879→ 43,216 total - Sale
Common Stock
2016-06-06$3.25/sh−5,543$18,040→ 33,023 total - Exercise/Conversion
Stock Option (right to buy)
2016-06-03−14,493→ 0 totalExercise: $0.65Exp: 2018-09-29→ Common Stock (14,493 underlying) - Exercise/Conversion
Stock Option (right to buy)
2016-06-03−5,353→ 0 totalExercise: $0.65Exp: 2020-01-29→ Common Stock (5,353 underlying) - Exercise/Conversion
Stock Option (right to buy)
2016-06-03−2,276→ 0 totalExercise: $0.65Exp: 2020-01-29→ Common Stock (2,276 underlying) - Exercise/Conversion
Stock Option (right to buy)
2016-06-03−3,809→ 0 totalExercise: $0.65Exp: 2020-06-25→ Common Stock (3,809 underlying) - Exercise/Conversion
Stock Option (right to buy)
2016-06-03−5,112→ 0 totalExercise: $0.65Exp: 2021-01-14→ Common Stock (5,112 underlying) - Exercise/Conversion
Stock Option (right to buy)
2016-06-03−2,732→ 0 totalExercise: $0.65Exp: 2022-12-23→ Common Stock (2,732 underlying)
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.21 to $3.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
- [F4]The Reporting Person was granted options to purchase these shares pursuant to the Issuer's 2005 Equity Incentive Plan. Each option become exercisable immediately upon grant.
- [F5]The Reporting Person was granted an option to purchase these shares pursuant to the Issuer's 2005 Equity Incentive Plan. The option became exercisable as to 33% of the shares underlying the option on December 23, 2013, with 2.79% of the shares underlying the option vesting monthly thereafter.
Documents
Issuer
EYEGATE PHARMACEUTICALS INC
CIK 0001372514
Entity typeoperating
Related Parties
1- filerCIK 0001372514
Filing Metadata
- Form type
- 4
- Filed
- Jun 6, 8:00 PM ET
- Accepted
- Jun 7, 5:42 PM ET
- Size
- 23.9 KB